The list for the next round of medicines that will ... reckons a chronic obstructive pulmonary disease (COPD) drug will be included – and is preparing to contribute to the process.

GSK was able to persuade NICE to change its mind after it provided further analyses on its use, as well as an additional price reduction. The drug’s list price is £840 per dose, but the price ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker ...

The deal kicks off with GSK paying South Korea-based ABL £38.5 million (about $49.1 million) up front. The drug delivery approach of ABL is based on Grabody, a platform technology that develops ...

The list is sorted in ascending order of hedge ... and endometrial cancer in addition to other drugs. GSK plc (NYSE:GSK) reported solid financial results for fiscal Q4 2024, reflecting strong ...

Pharmaceutical company GSK rounds out our list of best companies to buy. The firm’s innovative new product lineup and expansive list of patent-protected drugs create a wide economic moat ...

Big pharmaceutical companies including AstraZeneca, Sanofi, GSK and Eli Lilly have at least one U.S. manufacturing site for their drugs sold in China, records from China's National Medical ...

The Blujepa nod is the second that GSK can check off its list of the five expected approvals it aims to pick up this year. Next up are hopeful expansions for its antibody-drug conjugate Blenrep ...

The Food and Drug Administration on Tuesday approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker ...